Evidence map›Paper›PMID 32936530›Full record

ArticleESC heart failure2020

Predictive value of heart failure with reduced versus preserved ejection fraction for outcome in pulmonary embolism.

Slobodan Obradovic, Boris Dzudovic, Bojana Subotic, Jovan Matijasevic, Zorica Mladenovic, Aleksandar Bokan, Jadranka Trobok, Sandra Pekovic, Sonja Salinger-Martinovic, Ljiljana Jovanovic and 13 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Corrigendum.ESC heart failure · 2022
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 11 institutions in 5 countries.

Slobodan ObradovicClinic of Cardiology and Emergency Internal Medicine, Military Medical Academy, Belgrade, Serbia.
Boris DzudovicClinic of Cardiology and Emergency Internal Medicine, Military Medical Academy, Belgrade, Serbia.
Bojana SuboticClinic of Cardiology and Emergency Internal Medicine, Military Medical Academy, Belgrade, Serbia.
Jovan MatijasevicInstitute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia.
Zorica MladenovicClinic of Cardiology and Emergency Internal Medicine, Military Medical Academy, Belgrade, Serbia.
Aleksandar BokanInstitute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia.
Jadranka TrobokInstitute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia.
Sandra PekovicInstitute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia.
Sonja Salinger-MartinovicClinic of Cardiology, Clinical Center Nis, University of Niš, Niš, Serbia.
Ljiljana JovanovicInstitute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia.
Ljiljana KosClinic of Cardiology, Clinical Center Banja Luka, School of Medicine, University of Banja Luka, Banja Luka, Republic of Srpska, Bosnia and Herzegovina.
Tamara Kovacevic-PreradovicClinic of Cardiology, Clinical Center Banja Luka, School of Medicine, University of Banja Luka, Banja Luka, Republic of Srpska, Bosnia and Herzegovina.
Maja NikolicClinic of Cardiology, Clinical Center Kragujevac, School of Medicine, University of Kragujevac, Kragujevac, Serbia.
Vladimir MiloradovicClinic of Cardiology, Clinical Center Kragujevac, School of Medicine, University of Kragujevac, Kragujevac, Serbia.
Ana Kovacevic-KuzmanovicDepartment for Internal Medicine, General Hospital Pancevo, Pancevo, Serbia.
Nenad ZecDepartment for Internal Medicine, General Hospital Pancevo, Pancevo, Serbia.
Natasa Markovic-NikolicClinic of Cardiology, University Hospital Zvezdara, Belgrade, Serbia.
Ilija SrdanovicInstitute for Cardiovascular Medicine Vojvodina, School of Medicine, University of Novi Sad, Novi Sad, Serbia.
Zoran GluvicIntensive Care Unit, Clinic of Internal Medicine, Clinical Hospital Center Zemun, Belgrade, Serbia.
Srdjan KafedzicIntensive Care Unit, Clinic of Internal Medicine, Clinical Hospital Center Zemun, Belgrade, Serbia.
Sasa PancevackiIntensive Care Unit, Clinic of Internal Medicine, Clinical Hospital Center Zemun, Belgrade, Serbia.
Aleksandar NeskovicFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Stavros KonstantinidesCenter for Thrombosis and Hemostasis, Johannes Gutenberg University of Mainz, Mainz, Germany.
Military Medical Academy · RSZemun Hospital · RSInstitute for Pulmonary Diseases of Vojvodina · RSClinical Centre of Kragujevac · RSGovind Ballabh Pant Hospital · INUniversity of Banja Luka · BAUniversity of Novi Sad · RSJohannes Gutenberg University Mainz · DEKliničko Bolnički Centar Zvezdara · RSUniversity of Defence · RSUniversity of Nis · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis study aimed to investigate whether the risk of short-term mortality is different in pulmonary embolism (PE) patients who have heart failure with reduced ejection fraction (HFrEF) as compared with those with heart failure with preserved ejection fraction (HFpEF). METHODS AND

resultsPredictive value of HFrEF or HFpEF for 7-day (intrahospital) and 30-day all-cause mortality was determined in the cohort of 1055 out of 1201 consecutive acute PE patients from the Serbian multicentre PE registry. Patients were classified into either HFrEF or HFpEF group, according to guideline-proposed criteria. A 7-day (intrahospital) and 30-day all-cause mortality was 18.5% vs. 7.3% vs. 4.5% (P < 0.001) and 22.2% vs. 16.3% vs. 7.9% (P < 0.001) for patients with the history of HFrEF, HFpEF, and without HF, respectively. Multivariable analysis adjusted to age, gender, history of chronic obstructive pulmonary disease, diabetes mellitus, arterial hypertension, presence of atrial fibrillation, and mortality risk assessment at admission has shown that only HFrEF, but not HFpEF, was an independent predictor for 7-day mortality (hazard ratio 2.22, 95% confidence interval 1.25-4,38.41, P = 0.021) and neither HFrEF or HFpEF was an independent predictor for 30-day mortality. Among various admission parameters associated to PE outcome, only systolic pressure in HFrEF patients (P < 0.001), heart rate (P = 0.01), and right ventricle systolic pressure (P = 0.039) in HFpEF patients were significantly different in patients who died compared with those who survived at 7 days.

conclusionsOur study has shown that the presence of previous history of HFrEF, but not HFpEF, in acute PE is an independent risk factor for mortality at 7 days.

Indexed as

Ejection fractionHeart failureMortalityPulmonary embolism

Identifiers

PMID32936530
PMCPMC7754916
OpenAlexW3087564752

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.